Galena dives after participant recruiting suspended in VADIS study
Shares of Galena (GALE) are lower after a notice posted on clinicaltrials.gov that said recruiting for Galena study on VADIS is suspended. Galena is a biopharmaceutical company, focuses on developing and commercializing oncology therapeutics. Clinicaltrials.gov describes the purpose of the study: This randomized phase II trial studies how well nelipepimut-S plus GM-CSF vaccine therapy or sargramostim works in treating patients with breast cancer. Vaccines made from peptide or antigen and/or a person's white blood cells mixed with tumor proteins may help the body build an effective immune response to kill tumor cells that express breast cancer. It is not yet known whether nelipepimut-S plus GM-CSF vaccine or sargramostim is more effective in treating patients with breast cancer. According to a recent Bloomberg report, a Galena spokeswoman commented on voicemail, saying that "Galena targets VADIS study by year-end, possibly Q1." PRICE ACTION: Shares of Galena Biopharma are down 8.5% to $3.10 per share in afternoon trading.